National Cancer Institute  U.S. National Institutes of Health

Cancer Trends Progress Report – 2011/2012 Update

Skip to content
Progress Report  Home

Progress Report Tools
 Print this page
 Generate custom report

In the Report
Summary Tables
Early Detection
Bladder Cancer Treatment
Breast Cancer Treatment
Colorectal Cancer Treatment
Kidney Cancer Treatment
Lung Cancer Treatment
> Ovarian Cancer Treatment
Prostate Cancer Treatment
Life After Cancer
End of Life

Ovarian Cancer Treatment

The use of paclitaxel rose following its approval by the Food and Drug Administration (FDA), but use has decreased in the most recent year for patients with late-stage disease.

On this page:

Benefits of Treatment

An analysis of two pooled studies in early-stage ovarian cancer showed an increase in overall survival with the administration of chemotherapy. Guidelines suggest intraperitoneal (IP) chemotherapy for later stage ovarian cancer.

Back to Top


Percentage of individuals diagnosed with ovarian cancer who received chemotherapy by stage of diagnosis.

Back to Top

Period – 1991, 1996, 2002

Back to Top

Trends – From 1996 to 2002, for women with stage I or II, the use of chemotherapy was stable. Women with stage III and IV have had a decrease in the use of chemotherapy over the same time period.

Back to Top

Most Recent Estimates

In 2002, 56 percent of women with stage I or II ovarian cancer received chemotherapy compared to 72 percent of women with stage III or IV disease. An NCI patterns of care study of ovarian cancer is being planned for 2013.

Back to Top

Healthy People 2020 Targets

There are no Healthy People targets for cancer treatment, including for ovarian cancer treatment.

Back to Top

Groups at High Risk for Not Receiving Appropriate Treatment

Paclitaxel is recommended for the treatment of ovarian cancer. There has been a non-significant decrease in its use for women with stage III or IV disease between 1996 and 2002.

Back to Top

Key Issues

Taxol was approved for the treatment of ovarian cancer in December 1992. Between 1991 and 1996, the dissemination of taxol into community practice can be seen. There was a substitution of taxol for cyclophosphamide in those years.

The use of IP chemotherapy is recommended for late-stage ovarian cancer. Research is needed to examine the current use of IP therapy.

Back to Top

Additional Information on Ovarian Cancer Treatment

Back to Top

Back: Lung Cancer Treatment

National Cancer InstituteDepartment of Health and Human ServicesNational Institutes of

NIH... Turning Discovery Into Health